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ated	 according	 to	 two	 alternative	 histomorphologic	 classifications:	 World	 Health	
Organization	(WHO)	or	endometrial	 intraepithelial	neoplasia	(EIN)	system.	The	2017	





precancerous	EH,	and	endometrial	cancer	 (EC);	 (b)	 the	diagnostic	accuracy	of	PAX2	
immunohistochemistry	in	diagnosing	precancerous	EH,	defining	criteria	for	its	use.






































The	 EIN	 system	 categorizes	 EH	 into	 “benign	 EH”	 and	 “endo‐
metrial	 intraepithelial	neoplasia,”	based	on	a	combination	of	histo‐
morphologic	 criteria.2,3	 EIN	 classification	 is	 recommended	 by	 the	
American	College	of	Obstetricians	and	Gynecologists.5
On	 the	 other	 hand,	 the	 revised	 2014	WHO	 classification	 has	
used	 “atypical	 EH”	 and	 “endometrial	 intraepithelial	 neoplasia”	 as	
synonyms.1
Recently,	a	novel	 integration	of	both	classification	systems	has	










reliability	 of	 the	 differential	 diagnosis.9	 In	 particular,	 in	 the	 2017	
European	 Society	 of	 Gynaecological	 Oncology	 (ESGO)	 guide‐
lines	 (based	on	the	2016	European	Society	for	Medical	Oncology‐
ESGO‐European	Society	 for	Radiotherapy	&	Oncology	Consensus	
Conference),	 the	 immunohistochemical	 evaluation	of	paired	box	2	
protein	(PAX2)	has	been	recommended	to	distinguish	premalignant	
EH	from	benign	mimics.10	Nevertheless,	 it	 is	not	specified	 if	PAX2	
nuclear	expression	should	be	assessed	routinely	or	in	selected	cases,	
and	in	terms	of	complete	loss	or	only	decrease	of	expression.
In	 the	 literature,	 the	 changes	 of	 PAX2	 immunohistochemical	
expression	 from	NE	 to	 simple	 and	 complex	 EH	 (with	 and	without	
atypia),	 EIN,	 and	 endometrial	 cancer	 (EC)	 are	 not	 well	 defined.	
Furthermore,	it	is	unclear	if	the	PAX2 gene acts as an oncogene or 
a	 tumor	 suppressor	 in	 endometrial	 carcinogenesis.	 No	 systematic	




1.	 to	 determine	 the	 behavior	 of	 PAX2	 in	 endometrial	 carcino‐
genesis,	by	assessing	the	differences	in	PAX2	expression	among	
the above‐mentioned histologic categories;
2.	 to	 determine	 the	 diagnostic	 accuracy	 of	 PAX2	 immunohisto‐
chemistry	 in	differential	diagnosis	between	benign	and	precan‐
cerous	EH,	defining	the	optimal	criteria	for	the	interpretation	of	
PAX2	 immunostaining;	 for	 this	 purpose,	 we	 planned	 to	 assess	
how	 the	 accuracy	 changes	 according	 to	 the	 index	 test	 criteria	
(PAX2	complete	loss	or	even	only	decrease	of	expression)	and	ref‐
erence	standard	criteria	(WHO	or	EIN	system).




steps	 were	 conducted	 independently	 by	 two	 reviewers	 (AR,	 AT).	
The	two	authors	independently	performed	electronic	search,	inclu‐
sion	criteria,	eligibility	of	 the	studies,	 risk	of	bias,	data	extraction,	
and data analysis. Disagreements were resolved by discussion with 
a	third	reviewer	(GS).
The	 study	was	 reported	 according	 to	 the	 Preferred	 Reporting	
Item	 for	 Systematic	 reviews	 and	 Meta‐Analyses	 (PRISMA)	 state‐
ment11	 and	 the	 Synthesizing	 Evidence	 from	 Diagnostic	 Accuracy	
TEsts	(SEDATE)	guideline.12
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Several	 searches	 were	 conducted	 using	 EMBASE,	 OVID,	
MEDLINE,	Scopus,	Web	of	Sciences,	Cochrane	Library,	ClinicalTrial.





munohistochemical”;	 “immunohistochemistry”;	 “endometrial	 hyper‐
plasia”;	 “endometrial	 intraepithelial	 neoplasia”;	 “EIN”;	 “precancer”;	






review.	 Exclusion	 criteria	 were:	 sample	 size	 <10	 cases;	 language	
other	than	English;	case	reports.






Following	 the	 revised	 Quality	 Assessment	 of	 Diagnostic	
Accuracy	 Studies	 (QUADAS‐2),13	 four	 domains	 regarding	 risk	 of	
bias	were	 evaluated	 in	 each	 study:	 (1)	 patient	 selection	 (ie,	 if	 the	
patients	were	 consecutive);	 (2)	 index	 test	 (ie,	 if	 the	 assessment	of	
















1.	 PAX2	 nuclear	 expression	 (alternately	 dichotomized	 as	 “loss”	 or	




For	 meta‐analysis	 of	 diagnostic	 accuracy,	 the	 index	 test	 was	
PAX2	nuclear	expression,	whereas	the	reference	standard	was	his‐
tologic	type	of	EH,	dichotomized	as	“benign”	or	“precancerous”.








1.	 for	 the	 study	 assessing	 the	 rate	 of	 PAX2‐stained	 cells,	 PAX2	
loss	was	considered	as	0%	cell	staining,	whereas	PAX2	decrease	











F I G U R E  1  Flow	diagram	of	studies	identified	in	the	systematic	
review	(PRISMA	template	[Preferred	Reporting	Item	for	Systematic	
Reviews	and	Meta‐analyses])
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1.	 for	 the	 studies	 adopting	 the	WHO	 system,	 atypical	 EH	 (simple	
or	complex)	was	considered	as	 “precancerous,”	and	EH	without	









Univariate	 comparisons	 of	 PAX2	 expression	 were	 performed	





TA B L E  1   Immunohistochemical	assessment	of	PAX2	expression	in	the	included	studies
Study (ref)
Normal endometrium
Benign EH Precancerous EH
Endometrial cancerSimple EH (WHO) Complex EH (WHO)
Benign  
EH (EIN) Atypical EH (WHO) Premalignant EH (EIN)














28 0	(0) 5	(17.6) — 23 4	(17.4) 15 
(65.2)
— 84 49	(59) 76	(90.5) — — — — — 56 40	
(74.1)
52	(92.9) — ‐ — — — 15 3	(20) 14	(90.3) —
Kahraman 
201215
37 — — 80.8 ± 
18.5
— — — — 18 — — 88.6	±	
20.6
— — — — 19 — — 92.7	±	
11.6




— — — — — — — — 73 — 66	(90.4) — — — — — 41 — 38	(92) — — — — — — — — —
Joiner 
201417




— — — — —
Trabzonlu 
201714
— — — — — — — — — — — — 34 0	(0) 7	(20.6) 4.32	±	
1.06

















































manufacturer Clone Diluition Antigen retrieval
Monte	201018 USA 2006‐2008 n.r. Biopsies,	curettages Consecutive 41.8	±	6.1 50.3 ± 10.1 Clinical indication, 
sampling	device,	
age




Allison 201219 USA 1985‐2009 Cohort n.r. Randomized <39	to	>70 <39	to	>70 Age,	BMI Zymed Z‐RX2 1:100 EDTA 15 min Semi‐quantitative	proportional	
score








1:100 CC2 solution Mean	combined	staining	score	for	
each category
Upson	201216 USA 1995‐2005 Nested	
case 
control
















estimate	 adopting	 the	 random	 effect	 model	 of	 DerSimonian	 and	
Laird	and	reported	graphically	on	forest	plots,	with	95%	CI.
Statistical	 heterogeneity	 among	 the	 included	 studies	 was	
evaluated using the Higgins I2 statistic; heterogeneity was cate‐




categorized	 as	 absent	 for	AUC	≤	0.5,	 low	 for	 0.5	<	AUC	≤	0.75,	mod‐
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One	 study	 assessed	 EH	 according	 to	 both	 classification	 sys‐
tems.17	 Hence,	 it	 was	 included	 in	 both	 subgroups,	 whereas	 data	
according	 to	 only	 the	 EIN	 system	were	 used	 for	 total	 diagnostic	
accuracy.



















Details	 about	 PAX2	 immunohistochemical	 assessment	 are	





one	was	classified	at	unclear	 risk	because	 it	did	not	 report	 this	 in‐
formation,15	 and	 one	was	 high	 risk	 because	 it	 only	 selected	 cases	
previously	diagnosed	as	non‐atypical	hyperplasia.14 Concerns about 
the	applicability	of	this	domain	were	considered	high	for	one	study,	
because	it	assessed	only	EH	of	women	treated	with	progestin.16











categorized	 at	 low	 risk	 of	 bias,	 given	 that	 both	 the	 index	 and	 the	
reference	standard	were	performed	on	the	same	sample	and	for	all	
patients;	moreover,	 the	 latency	time	between	 index	and	reference	
standard	did	not	affect	the	results.
F I G U R E  2  A,	Assessment	of	risk	of	bias.	Summary	of	risk	of	bias	for	each	study.	Plus	sign:	low	risk	of	bias;	minus	sign:	high	risk	of	bias;	
question	mark:	unclear	risk	of	bias.	B,	Risk	of	bias	graph	about	each	risk	of	bias	item	presented	as	percentages	across	all	included	studies	
[Colour	figure	can	be	viewed	at	wileyonlinelibrary.com]




according	 to	 the	WHO	 system,	 PAX2	 loss	was	 significantly	more	
common	 in	 complex	 EH	 than	 simple	 EH	 and	NE	 (P < 0.0001),	 and	
in	 atypical	EH	 than	complex	EH	 (P = 0.0152).	A	decrease	of	PAX2	
expression	was	 significantly	more	 common	 in	 simple	 EH	 than	NE	
(P = 0.0429),	 in	complex	EH	than	simple	EH	(P = 0.0011),	and	in	EC	
than	simple	EH	(P = 0.0073).
Adopting	EIN	criteria,	PAX2	loss	was	significantly	more	common	
in	NE	than	benign	EH	 (P < 0.0001),	 in	EIN	than	benign	EH	and	NE	
(P < 0.0001),	 and	 in	 EC	 than	NE	 (P < 0.0001).	 PAX2	 decrease	was	
significantly	more	common	in	EIN	than	benign	EH	(P < 0.0001)	and	
NE	(P = 0.0011).
Considering	 both	 WHO	 and	 EIN	 system,	 PAX2	 loss	 was	 sig‐
nificantly	 more	 common	 in	 precancerous	 EH	 than	 benign	 EH	
(P < 0.0001),	and	in	EC	than	benign	EH	(P < 0.0001).	PAX2	decrease	
was	significantly	more	common	in	benign	EH	than	NE	(P < 0.0001),	
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expression	 in	 each	 histologic	 category	with	 related	P values were 
reported	in	detail	for	WHO,	EIN,	and	both	systems	together	in	the	
Supplementary	material	(Tables	S1‐S3,	respectively).
Regarding diagnostic accuracy assessment, three studies eval‐
uating	274	EH	were	included	in	the	meta‐analysis.14,17,19	In	all,	166	
(60.6%)	of	the	total	EH	were	benign	and	108	(39.4%)	were	precan‐









the included studies, the heterogeneity was high with I2	=	80%	for	




ing	 endometrial	 precancer	 with	 both	 classification	 systems	 were	
91%	 (95%	CI	84%‐95%)	and	37%	 (95%	CI	30%‐45%),	 respectively,	
with	 pooled	 LR+	 and	 LR−	 of	 2.45	 (95%	 CI	 0.51‐11.83)	 and	 0.23	
(95%	 CI	 0.13‐0.41),	 respectively.	 Pooled	 DOR	was	 11.37	 (95%	 CI	
3.82‐33.79).	 Among	 the	 included	 studies,	 the	 heterogeneity	 was	







loss	and	decrease	of	PAX2	expression	 in	217	EH	according	 to	 the	
WHO	 system	were	 included,	 respectively	 in	 the	 first	 and	 second	
subgroups.17,19	One	hundred	and	thirty‐eight	(63.6%)	of	the	total	EH	
were	benign	and	79	(36.4%)	were	premalignant.
On the other hand, two studies evaluating both loss and de‐
crease	of	PAX2	expression	in	114	EH	according	to	the	EIN	system	
were	 included,	 respectively	 in	 the	 third	and	 fourth	 subgroups.14,17 




76%	 (95%	CI	 65%‐85%)	 and	52%	 (95%	CI	 44%‐61%),	 respectively,	
with	pooled	LR+	and	LR−	of	1.59	(95%	CI	1.25‐2.04)	and	0.46	(95%	
CI	0.3‐0.71),	respectively.	Pooled	DOR	was	3.44	(95%	CI	1.86‐6.38).	











In	 subgroup	 3	 (PAX2	 loss	 and	 EIN	 system),	 pooled	 sensitivity	
and	 specificity	 of	PAX2	 loss	 in	 diagnosing	EIN	were	72%	 (95%	CI	







F I G U R E  4  Summary	receiver	operating	characteristic	curves	related	to	loss	(A)	and	decrease	(B)	of	paired	box	2	protein	expression	in	
differential	diagnosis	between	benign	and	premalignant	endometrial	hyperplasia	[Colour	figure	can	be	viewed	at	wileyonlinelibrary.com]
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(95%	CI	73%‐93%)	and	78%	 (95%	CI	66%‐88%),	 respectively,	with	









cantly	 more	 common	 in	 EC	 and	 precancerous	 EH	 than	 in	 benign	
EH,	demonstrating	that	PAX2	expression	decreases	in	endometrial	
carcinogenesis.
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production	at	the	transcriptional	level.24,25	The	expression	of	PAX2	
is	 upregulated	 indirectly	 by	 the	 estrogen	 receptor	 α	 pathway.26 
Nevertheless,	to	date,	the	role	of	PAX2	and	its	changes	of	expres‐
sion in endometrial carcinogenesis are still unclear, with the common 
suggestion	that	PAX2	expression	decreases	in	EC	and	precancer	and	
a	few	studies	advocating	an	opposing	viewpoint.15,26‐28
Although	one	study	among	 those	 included	 reported	 that	PAX2	






immunohistochemistry.29,30 To date, data regarding the molecular 
mechanisms	 of	 PAX2	 loss	with	 specific	 regard	 to	 endometrial	 car‐
cinogenesis	are	 lacking.	However,	pathway	models	 for	 the	possible	
tumor	 suppressor	 activity	 of	 PAX2	 in	 endometrial	 carcinogenesis	
might be suggested by studies about carcinogenesis in other tissues. 
In	 particular,	 several	 mechanisms	 have	 been	 proposed	 for	 tumor	
suppressor	activity	of	PAX2	in	ovarian	carcinogenesis.	PAX2	knock‐
down	 in	 fallopian	 tube	 epithelial	 cell	 lines	 increased	 expression	 of	
the	 stem	 cell	markers	CD44	and	SCA1	and	 reduced	 the	 capability	
of	 these	 cells	 to	 form	differentiated	epithelial	 luminal	 structures.31 
It	has	been	shown	in	murine	oviductal	epithelial	cells	that	wild‐type	










epithelium	 derived	 model	 of	 high‐grade	 serous	 ovarian	 carcinoma	
reduced	proliferation	and	metastasis	by	increasing	cyclo‐oxygenase	
subunit	 2	 and	 reducing	HTRA1	 (HtrA	 serine	 peptidase	 1)	 expres‐
sion.33	Altogether,	 these	 results	 suggest	 that	PAX2	 loss	may	be	an	
early	molecular	event	in	ovarian	cancer	progression	that	predisposes	
cells	 to	 further	mutations	 that	 can	 drive	 tumorigenesis,	 regardless	
of	the	cell	of	origin.34	Such	mechanisms	might	underlie	endometrial	
carcinogenesis.
However, a PAX2	 oncogenic	 action	 cannot	 be	 excluded	 in	 en‐
dometrial carcinogenesis, as suggested by Kahraman et al15 and 
other EC cell‐culture studies.26,27	 These	 findings	might	 indicate	 a	
PAX2	 gene	double	action	 (tumor	suppressor	and	oncogene)	 in	en‐








egory	 of	 complex	 EH	without	 atypia	might	 also	 include	 premalig‐
nant	 lesions,	 as	 suggested	by	 comparison	with	EIN	 classification.3 
Therefore,	 immunohistochemical	assessment	of	PAX2	might	assist	
histomorphologic	 examination	 to	 diagnose	 precancerous	 EH	 even	
before	the	appearance	of	overt	cytologic	atypia,	as	discussed	below.
















criteria,	 sensitivity,	 specificity,	 and	 DOR	 greatly	 increased.	 The	
highest	 diagnostic	 accuracy	 was	 found	 for	 the	 combination	 of	
















logic	atypia	 is	 still	 absent.	Such	a	 finding	 is	 in	accordance	with	
the	results	of	our	previous	review	regarding	Bcl‐2	expression	in	
EH.35	The	EIN	system	is	based	on	three	main	histomorphologic	
features	 (glandular	 crowding,	 lesion	 diameter	 >1	mm,	 cytology	
different	 from	 adjacent	 endometrium)	 and	 a	 careful	 exclusion	
of	benign	mimics	 (eg,	polyps,	 secretory	changes)	and	cancer.2,3 
PAX2	 loss	may	 be	 used	 as	 an	 adjuvant	 finding	 for	 the	 EIN	 di‐
agnosis	when	comparison	with	NE	 is	not	possible,	or	 there	 is	a	
secretory	pattern	as	background	endometrium,	as	suggested	by	
Quick	et	al.36





review	 specifically	 assessing	 the	 immunohistochemical	 expression	
changes	of	PAX2	in	NE,	benign	and	precancerous	EH,	and	EC,	evalu‐



















Both	 complete	 loss	 and	 decrease	 of	 PAX2	 expression	 were	 sig‐
nificantly	more	common	 in	EC	and	precancerous	EH	than	benign	
EH,	 suggesting	 a	 tumor	 suppressor	 action	 of	 the	 PAX2 gene in 
12  |     RAFFONE Et Al.
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